Healthcare >> CEO Interviews >> August 25, 2003

James Baker Jr. – Nanbio Corporation

MICHAEL F. NOLD is Chief Financial Officer and Director of Nanobio Corporation. Mr. Nold retired from Key Bank as an Executive Vice President following a 33-year commercial banking career that included 10 years at the former National Bank of Detroit. Present directorships are with Non-Profit Enterprise at Work, Washtenaw United Way, Assay Designs, Inc., and Technology Research Corporation. His formal education includes an MBA from the University of Chicago and a BSBA from Rockhurst University. Mr. Nold left retirement to assume the Chief Financial Officer position. Profile
DR. JAMES R. BAKER JR. is President, Chief Executive Officer, Chief Science Officer, and Chairman of the Board of NanoBio Corporation, Professor of Medicine and Chief of the Allergy Division at the University of Michigan Medical Center and the Director of the Center for Biologic Nanotechnology. Dr. Baker, Ruth Dow Doan Professor of Biologic Nanotechnology at the University of Michigan, completed his undergraduate education at Williams College in Williamstown, Massachusetts and his medical education at Loyola-Stritch School of Medicine in Maywood, Illinois. At the Walter Reed Army Medical Center in Washington, DC, he completed an internship, a residency in internal medicine, and a Fellowship in allergy and clinical immunology. Dr. Baker is a nationally and internationally recognized expert in immunology and biologic nanotechnogy, funded by approximately $25 million in federal grants and contracts with a research program of over $5 million in the current year. Because of his national recognition in nanotechnology, Dr. Baker was appointed in June 2003 to serve as a member on the newly formed Nanotechnology Technical Advisory Group (N-TAG) of the President's Council of Advisors on Science and Technology (PCAST) to the Executive Office of the President of the United States. Dr. Baker has published over 100 peer-reviewed papers as well as a number of book chapters and scholarly reviews. Profile
TWST: Could we begin with a brief historical sketch of NanoBio and a

picture of things as they are now?

Dr. Baker: The company was formed approximately three years ago to

commercialize a new